Skip to main content

Heron Therapeutics, Inc 10-Q for FY2026 Q3

Heron Therapeutics, Inc. (HRTX)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Heron Therapeutics, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$35.25M
down 7.8% from $38.21M a year earlier
Net loss
$5.01M
compared with a net loss of $17.5M a year earlier
Diluted EPS
-$0.03
compared with -$0.10 a year earlier